For example, the well-known immune checkpoint inhibitor pembrolizumab is used to treat various types of cancer, including melanoma and triple-negative breast cancer (TNBC), as it targets PD-1 (PDCD1) and interferes with PD-L1 (CD274) interaction. Here, PDCD1 is linked to melanoma.